DrT, i thought i had alreday asked this question but it seems i failed to post it.
I am very comforted by the fact that we have independant identification of Zantrene as an FTO inhibitor and these other independant stuidies abour T2D.
Is there a process for having encouraging independent verification of the cardio protective capabilities? At the moment it is only our commissioned studies that have identified this application. Would help spread the word as well as prove up the principle. Also peer review seems normal part of the process. Will there be a paper published in a journal or at conference that invites peer review?
Ann: Quarterly Activity Report & Appendix 4C, page-42
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.58 |
Change
0.055(3.62%) |
Mkt cap ! $268.4M | |||
| Open | High | Low | Value | Volume |
| $1.56 | $1.61 | $1.56 | $106.0K | 67.13K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 649 | $1.58 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.59 | 3000 | 1 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| RAC (ASX) Chart |